Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug that enhances glutamate transmission in brain being evaluated for fragile X

28.08.2002


Rush is one of only two sites in nation testing the drug that may provide new treatment option

Physicians at Rush-Presbyterian St. Luke’s Medical Center have begun to recruit patients as part of a clinical research study that will evaluate the effectiveness of a new drug as a potential treatment for fragile X syndrome and autism.

The trials are taking place at Rush and the University of California, Davis. The principal investigators in the study are Dr. Elizabeth Berry-Kravis, a pediatric neurologist at Rush-Presbyterian St. Luke’s Medical Center; and Dr. Randi J. Hagerman, medical director, M.I.N.D. Institute, School of Medicine, University of California, Davis. Dr. Edwin Cook an expert in autism at the University of Chicago contributed to the development of the clinical protocol.



"Currently there are no therapies on the market to treat cognitive deficits associated with fragile X syndrome or autism," said Berry-Kravis. "However, in the past five years, basic research has led to an improved understanding of these diseases and a number of scientists have suggested that the use of a drug to enhance glutamate transmission could be beneficial." The study will evaluate CX516 (Ampalex®), an Ampakine® compound, which has been proven to enhance glutamate transmission in the brain through activation of AMPA receptors. Ampalex® is made by Cortex Pharmaceuticals which will provide the study medication. The research is funded by the FRAXA Research Foundation.

Fragile X is an inherited disorder and is the most common cause of inherited mental retardation, affecting 1 in 2,000 males and 1 and 4,000 females. Symptoms of fragile X syndrome include mental impairment ranging from learning disabilities to mental retardation, attention deficit and hyperactivity, anxiety and unstable mood, autistic-like behaviors, long face, large ears, flat feet, and hyperextensible joints, especially fingers. "Once you have a patient with fragile X syndrome, that’s a big red flag because that means the mutation has been in the family in a silent form for years," says Berry-Kravis.

Males are typically more severely affected than females. Although most males have mental retardation, only one-half of females have intellectual impairment (which tends to be milder in females); the rest have either normal IQ or learning disabilities. Emotional and behavioral problems are common in both sexes. Currently there are no therapeutic treatments for the learning problems associated with the disease, although medications for anxiety and ADHD are used to treat behavioral symptoms. Rush-Presbyterian-St. Luke’s Medical Center is the only clinical site for care of fragile X patients in the Chicago area.

Autism is a complex developmental disability that typically appears during the first three years of life. The result of a neurological disorder that affects the functioning of the brain, autism and its associated behaviors have been estimated to occur in as many as 2 to 6 in 1,000 individuals. Autism is four times more prevalent in males than in females.

A variety of scientific evidence suggests that increasing glutamate neuronal transmission may be beneficial in autism and in fragile X syndrome. Imaging studies demonstrate that areas of the brain that are extremely rich in glutamate transmission are less active in autistic patients. Molecular studies suggest that although genes involved in the AMPA-type glutamate receptor are more active in autistic patients, the density of AMPA-type glutamate receptors is decreased. Drugs that reduce glutamatergic transmission induce symptoms similar to those seen in autistic patients. Taken together, these facts suggest that enhancing AMPA receptor activity may be beneficial in autistic patients.

The scientific logic for using an AMPA receptor activator in fragile X syndrome is even more compelling because of recent findings regarding the direct impact of the genetic defect in fragile X on neural cell activity. The genetic defect results in the reduction or absence of an important protein, FMRP. FMRP is believed to play an important role in allowing normal levels of AMPA receptor proteins to be made - in the absence of FMRP, AMPA receptors are decreased and show lower activity levels. The abnormal AMPA receptor activity is likely related to the abnormal connections seen between neurons in the brains of those with fragile X syndrome. Increasing the activity of AMPA receptors with an Ampakine® may to some degree overcome the reduced number of AMPA receptors, with resulting improvements in brain connections in individuals with fragile X syndrome.

The design of the Phase II clinical study is a randomized double-blind placebo controlled trial lasting four weeks. Fifty patients from the Chicago area will be recruited for the study. It is anticipated that enrollment will occur over a two-year period. Outcome measures will include testing in four domains of attention and executive function; spatial and verbal/auditory memory; language; and behavior.

John Pontarelli | EurekAlert!

More articles from Health and Medicine:

nachricht Why might reading make myopic?
18.07.2018 | Universitätsklinikum Tübingen

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Metal too 'gummy' to cut? Draw on it with a Sharpie or glue stick, science says

19.07.2018 | Materials Sciences

NSF-supported researchers to present new results on hurricanes and other extreme events

19.07.2018 | Earth Sciences

Scientists uncover the role of a protein in production & survival of myelin-forming cells

19.07.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>